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OBJECTIVE: To assess the cost-effectiveness of photo-
dynamic therapy (PDT) with verteporﬁn for the treatment
of predominantly classic, subfoveal choroidal neovascu-
larisation (CNV) secondary to age-related macular 
degeneration (AMD) relative to no treatment.
METHODS: This analysis examines the cost-effectiveness
of PDT using verteporﬁn in patients with predominantly
classic CNV secondary to AMD, based on results of 
the TAP study, a multicentre, double-blind, randomised,
placebo-controlled trial. Data on visual acuity levels were
collected for 24 months, with an option of a further 12
months. Patients with visual acuity scores above the level
of legal blindness in Australia (34 letters or less) were
deﬁned as not blind. The proportion of patients not
legally blind at each three month interval was plotted on
a ‘vision curve’, extrapolated to 60 months and the area
under the curve calculated for each group. The difference
in area under the curve between groups is the vision years
gained from treatment. A costing analysis was also 
performed, based on an average of 3.4 treatments in 
the ﬁrst year, 2.1 in the second year and 1.2 in the third 
year. Costs of permanent nursing home entry, home and
community care, and falls—all resulting from declining
vision—were also included in the analysis.
RESULTS: The incremental cost of PDT with verteporﬁn
compared with no treatment varied between $13,762 and
$15,031 over the ﬁve-year period, depending on assump-
tions made regarding data extrapolation. Vision years
gained over this time varied between 0.7552 and 1.0389.
This corresponds to an incremental cost per vision year
gained of between $13,246 and $19,903, which sen-
sitivity analyses have shown to be robust to changes in
the value of key variables.
CONCLUSIONS: PDT with verteporﬁn represents a cost-
effective intervention in the proposed population. There
is currently no alternative treatment for patients with pre-
dominantly classic, subfoveal CNV secondary to AMD.
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THE PATIENTS’ PERCEPTION OF THEIR
PSORIASIS AND ITS TREATMENT THROUGH A
DIARY
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OBJECTIVES: The purpose of this study is to report 
preliminary ﬁndings of patient’s perception of their 
psoriasis and its treatment. SPOT is a longitudinal,
prospective, observational, programme. 2000 patients
with mild to moderate psoriasis will be recruited. (1000
Chronic Psoriasis Patient & 1000 New Psoriasis Patient).
METHODS: In this study, patients record, weekly, in 
a diary, their perception concerning satisfaction with
treatment, its side-effects and how it has been applied.
RESULTS: At this time we received 220 diaries ﬁlled in
during 4 weeks (50.7% of the patients followed since 4
weeks). The 2 populations are balanced. At the end of the
ﬁrst week, 14% of the population is unsatisﬁed with its
treatment and 75% declared an improvement of their
health state. The treatment compliance was evaluated, at
the end of the ﬁrst week 91% of the patients stated that
they are treating themselves 5 days per week or more, and
only 75% of the patients stated it at the end of the fourth
week. In this ﬁrst analysis we essentially focused on the
most often expressed treatment’s side effects: Burning
Sensation -BS-, Tearing Sensation (TS), Itching (I) and
Drying (D). At the end of the fourth week, for each
patient declaring a side-effect during the ﬁrst week, one
can note that the BS is reduced by 80%, the TS by 70%,
the I by 57% and the D by 48%.
CONCLUSION: The ﬁrst results of this program show
evidence of the patients support towards those types of
study and the methodology used. The non persistence 
of the most often expressed treatment’s side effects at 
the end of the 4 ﬁrst weeks demonstrate that a relevant
patient management is an alternative.
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OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients in France.
METHOD: 4.500 anonymous questionnaires (comprised
of two scales: the Psoriasis Disability Index (PDI) plus 10
questions concerning treatment and evolution of 
psoriasis) were sent, via a Psoriasis Patient Support
Group (APLCP).
RESULTS: 2.423 questionnaires were returned: response
rate 53%. An analysis of the ﬁrst 1866 questionnaires
was realised. The sex ratio Men (M)/Women (W) was:
47/53. Mean age: 51 years. Mean age of diagnosis: 22
years. The average to the total score was 9,64 (sd 5.2 rank
0 to 28) i.e. 21,6 (sd: 12.4) when reported to a scale of
0 to 100. No difference was observed between M and W
for the global handicap score. Psoriasis had a greater
adverse affect on 16–55 year-old patients in their social
relationships, leisure activities and how well they keep
their house than older subjects. Long-standing psoriasis
did not cause more handicap to people than psoriasis
